Looney Lab

The team: John Looney, M.D., Professor of Medicine and Environmental Medicine

                        Thomas Conley, Technician

                         Maria Allen, Health Project Coordinator

                         Debbie Campbell, RN, Health Project Coordinator

                         Emily Cushing, Health Project Coordinator

John Looney, M.D.
     Dr. Looney's research interests include aging and immunity, follicular dendritic cells, immune effects of pregnancy, and the biology of synovial fibroblasts.

     Dr. Looney has active studies in rheumatoid arthritis and lupus. For more information on the studies in rheumatoid arthritis, contact Maria Allen or Debbie Campbell at 585-275-1635. For more information on the studies in lupus, contact Emily Cushing at 585-275-7167.

Funding

     Dr Looney receives funding from the Lupus Clinical Trial Consortium, the NIH, Genetech, Amgen, Feinstein Institute for Medical Research, Hoffman-LaRoche, Contin, Bristol-Myers Squibb, Human Genome, and Wyeth.

Publications

     Dr. Looney's most recent publications include:

Looney, R., Anolik, J., and Sanz, I. Treatment of SLE with Anti-CD20 Monoclonal Antibody. Curr Dir Autoimmun 8:193, 2005.

Ping Li, MS, Edward M. Schwarz, PhD, Regis J. O’Keefe, MD, PhD, Lin Ma, MS, R. John Looney, MD, Christopher T. Ritchlin, MD, Brendan F. Boyce, MD, and Lianping Xing, PhD. Systemic TNFa mediates an increase in peripheral CD11bhi osteoclast precursors in TNFa transgenic mice. Arthritis & Rheumatism. 50(1):265-76, 2004.

Claus AM, Totterman SM, Sychterz CJ, Tamez-Peña JG, Looney RJ, Engh CA Sr. Computed Tomography to Assess Pelvic Lysis After Total Hip Replacement. Clinical Orthopaedics and Related Research. 422:167-74, 2004.

Joshi S, Scott G, Looney RJ. A successful challenge in a patient with vancomycin-induced linear IgA dermatosis. Annals of Allergy, Asthma & Immunology. 93(1):101-3, 2004.

Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B Cell Depletion as a Novel Treatment for Systemic Lupus Erythematosus: A Phase I/II Dose-escalation Trial of rituximab. Arthritis and Rheumatism. 50(8):2580-9, 2004.

For a complete list of Dr. Looney's publications, please use the following link: publications.